Mitochondrial Ca 2+ controls pancreatic cancer growth and metastasis by regulating epithelial cell plasticity.
Jillian S WeissenriederJessica PeuraUsha PaudelNikita BhaleraoNatalie WeinmannCalvin JohnsonMaximilian WengynRebecca DragerEmma Elizabeth FurthKarl SiminMarcus RuscettiBen Z StangerAnil K RustgiJason R PitarresiJ Kevin FoskettPublished in: bioRxiv : the preprint server for biology (2024)
Endoplasmic reticulum to mitochondria Ca 2+ transfer is important for cancer cell survival, but the role of mitochondrial Ca 2+ uptake through the mitochondrial Ca 2+ uniporter (MCU) in pancreatic adenocarcinoma (PDAC) is poorly understood. Here, we show that increased MCU expression is associated with malignancy and poorer outcomes in PDAC patients. In isogenic murine PDAC models, Mcu deletion ( Mcu KO ) ablated mitochondrial Ca 2+ uptake, which reduced proliferation and inhibited self-renewal. Orthotopic implantation of MCU-null tumor cells reduced primary tumor growth and metastasis. Mcu deletion reduced the cellular plasticity of tumor cells by inhibiting epithelial-to-mesenchymal transition (EMT), which contributes to metastatic competency in PDAC. Mechanistically, the loss of mitochondrial Ca 2+ uptake reduced expression of the key EMT transcription factor Snail and secretion of the EMT-inducing ligand TGFβ. Snail re-expression and TGFβ treatment rescued deficits in Mcu KO cells and restored their metastatic ability. Thus, MCU may present a therapeutic target in PDAC to limit cancer-cell-induced EMT and metastasis.
Keyphrases
- epithelial mesenchymal transition
- oxidative stress
- transforming growth factor
- poor prognosis
- endoplasmic reticulum
- signaling pathway
- transcription factor
- protein kinase
- small cell lung cancer
- squamous cell carcinoma
- induced apoptosis
- binding protein
- type diabetes
- diabetic rats
- end stage renal disease
- newly diagnosed
- traumatic brain injury
- metabolic syndrome
- cell death
- ejection fraction
- papillary thyroid
- dna binding